All Insights White Paper Econometric Analysis Of Biopharmaceutical Transfer Pricing

    Econometric Analysis Of Biopharmaceutical Transfer Pricing

    Commercial Analytics

    Econometric Analysis Of Biopharmaceutical Transfer Pricing

    The shift to commercializing specialty medicines, wheremarket performance will be predicated on the demonstrationand delivery of scientific evidence, will mean the importanceof intangible assets like IP will be fundamental to future biopharmaceutical financial success.

    Download White Paper
    Econometric Analysis Of Biopharmaceutical Transfer Pricing

    The shift to commercializing specialty medicines, where market performance will be predicated on the demonstration and delivery of scientific evidence, will mean the importance of intangible assets like intellectual property (IP) will be fundamental to future biopharmaceutical financial success. The global nature and internal structure of biopharmaceutical multinational corporations (MNCs) means that the location of commercialization is often different from where IP is developed. Therefore, understanding the financial implications of transfer pricing caused by differentials in country corporate income tax rates can legally and significantly minimize country tax liabilities.

    The econometric analysis outlined here can also help generate greater drug financial returns that can be used to plow back into R&D, the future lifeblood of any biopharmaceutical company, especially given the increasing cost and risk of R&D for specialty medicines. This white paper also demonstrates a different area not traditionally thought of where commercial analytics can be successfully applied for biopharmaceutical companies given changes in the biopharmaceutical external environment.

    Dr. George A. Chressanthis is currently Principal Scientist at Axtria. He brings a unique combination of professional experiences into the analysis of strategic and operational issues affecting the biopharmaceutical industry.

    Fill in your details to get a copy of this whitepaper, and contact us at insights@axtria.com for any questions.

    Contact us at insights@axtria.com with any questions.

    Complete the brief form to download the white paper

    Recommended insights

    Econometric Analysis Of Biopharmaceutical White Paper

    Blog

    Evaluation Of Marketing Strategies For Rare Diseases – A Discussion

    Econometric Analysis Of Biopharmaceutical White Paper

    Blog

    Implications from HEOR and RWE Models for Biopharmaceutical Commercial Analytics

    Econometric Analysis Of Biopharmaceutical White Paper

    White Paper

    Econometric Analysis Of Biopharmaceutical Transfer Pricing